Thyroid Tablets, USP 30 mg

  • Potential for the Product to be Superpotent
  • Company: Vitruvias Therapeutics, Inc
  • Drugs
  • FDA
  • August 21, 2026

Product details

  • Thyroid Tablets, USP 30 mg

Company announcement

Vitruvias Therapeutics Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg due to confirmed potential for superpotency.

The affected lot was distributed nationwide in the USA from January 31, 2025, to September 30, 2025.

No adverse events have been reported to date in relation to this recall.

Risk:

Consumption of superpotent Thyroid tablets can cause hyperthyroidism (overactive thyroid) including, but not limited to, weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances. The patient population at greater risk from superpotent thyroid are elderly, pregnant women, and infants, especially over extended periods of time. Excess levels of thyroid hormones in the elderly have been associated with adverse outcomes, particularly to cardiac health. Overtreatment of hypothyroidism in pregnancy is associated with a higher rate of maternal and fetal complications, including premature delivery and low birth weight. Overtreatment of hypothyroidism in infants may have negative effects on growth and development. To date, Vitruvias Therapeutics has not received any reports of adverse events known to be related to this recall.

Impacted states: Nationwide

Products:

- Thyroid Tablets, USP 30 mg (UPC code(s): 6968016600)

Contact

For more information, call (256) 239-9373 or email safety@vitruvias.com.

View the original FDA notice

Browse all recalls

Related recalls